# Preclinical Wet-Lab Validation Protocol (SOP)

**Standard Operating Procedure:** In Vitro & In Vivo Validation of 3D-Bioprinted Encapsulated Islet Scaffolds  
**Project:** T1D Encapsulation & Hypoimmune Organoid Digital Twin  
**Target Audience:** Wet-Lab Biochemists, Cell Culture Specialists, Bioengineers  
**Date:** July 2026  
**File:** [wet_lab_validation_protocol.md](file:///home/bezoom/storage/Projects/%D0%94%D0%B8%D0%B0%D0%B1%D0%B5%D1%82/docs/wet_lab_validation_protocol.md)

---

## 1. Objective

This protocol outlines step-by-step procedures to validate predictions from the `t1d_simulator` digital twin regarding:
1. Core oxygenation and cell viability in 3D Gyroid scaffolds ($pO_2 \ge 40\ \text{mmHg}$).
2. Foreign Body Reaction (FBR) thickness ($L_{fib} < 20\ \mu\text{m}$) using Zwitterionic SBAA/CBAA hydrogel coatings.
3. IBMIR prevention ($>90\%$ 48h cell retention) via Lipid-PEG-LMWH heparinization.
4. Efficacy in mouse omental pouch implantation models.

---

## 2. Materials & Reagents

- **Cells**: Human iPSC-derived $\beta$-cell clusters (SC-$\beta$) or MIN6 pseudoislets ($50\ \text{M/mL}$).
- **Hydrogel Matrix**: $2.0\%$ Ultra-pure Alginate + Zwitterionic SBAA (Sulfobetaine methacrylate) copolymer.
- **Surface Functionalization**: Lipid-PEG-LMWH (Low Molecular Weight Heparin) conjugate ($1.0\ \text{mg/mL}$).
- **Oxygen Release Particles**: Perfluorooctyl bromide (PFOB) nanoemulsion ($10\%\ \text{v/v}$).
- **3D Bioprinter**: Extrusion / SLA bioprinter loaded with Gyroid TPMS STL CAD file (`stl_files/omental_scaffold_gyroid.stl`).

---

## 3. Protocol Steps

### Phase A: 3D Bioprinting & Construct Fabrication
1. Suspend SC-$\beta$ organoids in alginate-SBAA hydrogel at $50\ \text{M cells/mL}$.
2. Load STL geometry `omental_scaffold_gyroid.stl` ($200\ \mu\text{m}$ wall thickness, $300\ \mu\text{m}$ channel diameter).
3. Print scaffold into $100\ \text{mM}\ \text{CaCl}_2$ crosslinking bath; incubate for 10 minutes.
4. Dip-coat scaffold in $1.0\ \text{mg/mL}$ Lipid-PEG-LMWH solution for 15 minutes to form anti-IBMIR nanolayer.

### Phase B: In Vitro Hypoxia & Viability Assay
1. Transfer constructs to hypoxic incubator ($1\%\ \text{O}_2 / 7.6\ \text{mmHg}$ or $5\%\ \text{O}_2 / 38\ \text{mmHg}$) for 48 hours.
2. Stain with Live/Dead Assay (Calcein-AM / Ethidium Homodimer-1).
3. Image via confocal microscopy (z-stack through $500\ \mu\text{m}$ depth).
4. **Acceptance Criteria**: Core viability $> 85\%$, matching `t1d_simulator` prediction for Gyroid topology.

### Phase C: In Vivo Mouse Omental Pouch Implantation
1. Anesthetize C57BL/6 mice (or STZ-induced diabetic immunodeficient NSG mice).
2. Laparotomy: expose the greater omentum.
3. Deploy 3D Gyroid construct into the omental pouch; secure with 6-0 prolene suture.
4. Monitor 30-day CGM glucose levels.
5. **Histology Endpoint (Day 30)**: Harvest graft, stain with H&E, Masson's Trichrome, and anti-CD31 (capillaries). Measure fibrotic capsule thickness $L_{fib}$.
